









Markets
/
Stocks
/
nasdaq-slno
/

Soleno Therapeutics Inc

SLNO

30.265USD

-1.595-5.01%

Market hours （ET）Quotes delayed by 15 min

2.81MMarket Cap

75.12P/E TTM



Soleno Therapeutics Inc

30.265

-1.595-5.01%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Soleno Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Soleno Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 105.08.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Soleno Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

13 / 391

Overall Ranking

80 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Soleno Therapeutics Inc Highlights

StrengthsRisks

Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 74.58, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 67.25M shares, increasing 5.30% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 129.04K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.73.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

103.583

Target Price

+225.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Soleno Therapeutics Inc is 9.17, ranking 11 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.17

Change



Financials

9.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Soleno Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Soleno Therapeutics Inc is 6.81, ranking 214 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 74.58, which is 35.14% below the recent high of 100.79 and 140.45% above the recent low of -30.17.

Score

Industry at a Glance

Previous score

6.81

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Soleno Therapeutics Inc is 8.77, ranking 59 out of 391 in the Biotechnology & Medical Research industry. The average price target is 110.00, with a high of 145.00 and a low of 75.00.

Score

Industry at a Glance

Previous score

8.77

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

103.583

Target Price

+225.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Soleno Therapeutics Inc

SLNO

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Soleno Therapeutics Inc is 6.82, ranking 127 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 38.13 and the support level at 25.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.02

Change

-0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.700

Sell

RSI(14)

27.758

Sell

STOCH(KDJ)(9,3,3)

20.020

Neutral

ATR(14)

1.953

High Vlolatility

CCI(14)

-103.262

Sell

Williams %R

94.687

Oversold

TRIX(12,20)

-0.909

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

31.362

Sell

MA10

32.345

Sell

MA20

35.327

Sell

MA50

38.615

Sell

MA100

43.480

Sell

MA200

58.188

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Soleno Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 125.22%, representing a quarter-over-quarter increase of 14.94%. The largest institutional shareholder is PRFDX, holding a total of 3.26M shares, representing 6.31% of shares outstanding, with 34.39% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

6.06M

+14.10%

Fidelity Management & Research Company LLC

6.53M

+102.30%

Wellington Management Company, LLP

2.31M

+272.30%

T. Rowe Price Associates, Inc.

Star Investors

3.85M

+12.49%

BlackRock Institutional Trust Company, N.A.

2.94M

+17.24%

The Vanguard Group, Inc.

Star Investors

2.80M

+12.79%

Avoro Capital Advisors LLC

2.58M

+25.75%

State Street Investment Management (US)

2.17M

+54.67%

Fidelity Institutional Asset Management

1.47M

+1216.63%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Soleno Therapeutics Inc is 4.54, ranking 80 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -2.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.